PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts

Purpose: Checkpoint kinase 1 (Chk1) plays a critical role in the activation of mitotic spindle checkpoint and DNA damage checkpoint. We examined the preclinical use of the Chk1 inhibitor PF-00477736 as a docetaxel-sensitizing agent. Specifically, we investigated the correlation between PF-00477736–mediated modulation of biomarkers and the sensitization of docetaxel efficacy. Experimental Design:In vitro and in vivo studies using COLO205 and other cell lines were done to assess PF-00477736–induced enhancement of docetaxel efficacy and effects on associated biomarkers. Results: PF-00477736 significantly enhanced the docetaxel-induced efficacy in tumor cells and xenografts. Docetaxel induced dose- and time-dependent increase in the levels of phosphorylated Chk1 (Ser345), phosphorylated histone H3 (Ser10), and γH2AX foci and promoted the cytoplasmic localization of phosphorylated Cdc25C (Ser216). PF-00477736 cotreatment suppressed docetaxel-induced changes in phosphorylated histone H3 and cytoplasmic phosphorylated Cdc25C (Ser216) levels and concurrently sensitized the docetaxel-induced apoptosis. Docetaxel alone or in combination with PF-00477736 induced significant antiproliferative activity in xenografts, shown via [18F]FLT-PET imaging. However, changes in [18F]FLT uptake did not reflect the potentiation of docetaxel efficacy. In contrast, bioluminescence imaging showed that PF-00477736 sensitized docetaxel-induced suppression of tumor survival. Conclusions: Docetaxel triggers mitotic spindle checkpoint activation at low concentrations and activates both the DNA damage checkpoint and the spindle checkpoint at high concentrations. In combination with docetaxel, PF-00477736 abrogates the mitotic checkpoint, as well as the DNA damage checkpoint, and results in sensitization to docetaxel. Chk1 inhibitor PF-00477736 offers a therapeutic potential for the enhancement of taxane therapy.

• Publication year

  2009

• Venue

  Clinical Cancer Research

• Publication date

  2009-07-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-08-3272PMID 19584159
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

  2010cited by this paper
• Advancing Bioluminescence Imaging Technology for the Evaluation of Anticancer Agents in the MDA-MB-435-HAL-Luc Mammary Fat Pad and Subrenal Capsule Tumor Models

  2009cited by this paper
• Imaging Proliferation to Monitor Early Response of Lymphoma to Cytotoxic Treatment

  2008cited by this paper
• AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

  2008cited by this paper
• New taxanes in development

  2008cited by this paper
• Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

  2008cited by this paper
• Taxanes, microtubules and chemoresistant breast cancer.

  2008cited by this paper
• G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

  2008cited by this paper
• DNA Damage Detection and Repair Pathways—Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy

  2008cited by this paper
• FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine.

  2007cited by this paper
• AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis

  2007cited by this paper
• Imaging Update: New Windows, New Views

  2007cited by this paper
• Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway

  2007cited by this paper
• Targeting Checkpoint Kinase 1 in Cancer Therapeutics

  2007cited by this paper
• Whole-Body Optical Imaging in Animal Models to Assess Cancer Development and Progression

  2007cited by this paper
• Chk1: a double agent in cell cycle checkpoints.

  2007cited by this paper
• Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis

  2007cited by this paper
• Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo

  2007cited by this paper
• Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer

  2007cited by this paper
• Positron emission tomography imaging as a key enabling technology in drug development.

  2007cited by this paper
• Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT, and bioluminescence imaging.

  2007cited by this paper
• Advances in optical imaging and novel model systems for cancer metastasis research

  2007cited by this paper
• Chk1 is required for spindle checkpoint function.

  2007influential reference
• 3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer.

  2007cited by this paper
• Specific Role of Chk1 Phosphorylations in Cell Survival and Checkpoint Activation

  2007cited by this paper
• CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo

  2007cited by this paper
• γ-H2AX in Cancer Cells: A Potential Biomarker for Cancer Diagnostics, Prediction and Recurrence

  2006cited by this paper
• A role of the mitotic spindle checkpoint in the cellular response to DNA replication stress

  2006cited by this paper
• Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells

  2005cited by this paper
• Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics

  2005cited by this paper
• Optical imaging in drug discovery and diagnostic applications.

  2005cited by this paper
• Targeting the checkpoint kinases: chemosensitization versus chemoprotection

  2004cited by this paper
• Imaging of bioluminescent LNCaP‐luc‐M6 Tumors: A new animal model for the study of metastatic human prostate cancer

  2004cited by this paper
• Checking on DNA damage in S phase

  2004cited by this paper
• Aurora kinases dawn as cancer drug targets

  2004cited by this paper
• [18F]FLT-PET in oncology: current status and opportunities

  2004cited by this paper
• Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers.

  2003cited by this paper
• Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints

  2002cited by this paper
• Abrogation of the S Phase DNA Damage Checkpoint Results in S Phase Progression or Premature Mitosis Depending on the Concentration of 7-Hydroxystaurosporine and the Kinetics of Cdc25C Activation*

  2002cited by this paper
• Paclitaxel‐induced cell death

  2000cited by this paper
• Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.

  2000cited by this paper
• The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01*

  2000cited by this paper
• Anticancer drug targets: cell cycle and checkpoint control.

  1999cited by this paper
• rad-Dependent Response of the chk1-Encoded Protein Kinase at the DNA Damage Checkpoint

  1996cited by this paper

• Molecular Imaging for Biomimetic Nanomedicine in Cancer Therapy: Current Insights and Challenges.

  2025cites this paper
• A multiparametric screen uncovers FDA-approved small molecules that potentiate the nuclear mechano-dysfunctions in ATR-defective cells

  2024cites this paper
• Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma

  2022cites this paper
• Chk1 Inhibition Ameliorates Alzheimer’s Disease Pathogenesis and Cognitive Dysfunction Through CIP2A/PP2A Signaling

  2022cites this paper
• Roles of Claspin in regulation of DNA replication, replication stress responses and oncogenesis in human cells

  2021cites this paper
• Deficiency of NEIL3 Enhances the Chemotherapy Resistance of Prostate Cancer

  2021cites this paper
• Upregulation of GRIM‐19 augments the sensitivity of prostate cancer cells to docetaxel by targeting Rad23b

  2020cites this paper
• DNA damage checkpoint kinases in cancer

  2020cites this paper
• Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells

  2019cites this paper
• Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms

  2019cites this paper
• Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials.

  2018cites this paper
• DNA damage response following X-irradiation in oral cancer cell lines HSC3 and HSC4.

  2018cites this paper
• Preclinical Profiles and Contexts for CHK1 and CHK2 Inhibitors

  2018cites this paper
• Targeting CHK1 for Cancer Therapy: Rationale, Progress and Prospects

  2018cites this paper
• Targeting ATR for Cancer Therapy: ATR-Targeted Drug Candidates

  2018cites this paper
• Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.

  2017cites this paper
• ATR/CHK1 inhibitors and cancer therapy.

  2017cites this paper
• DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy.

  2017cites this paper
• Targeting DNA Damage Response Pathways in Cancer

  2017cites this paper
• Targeting the ATR-CHK1 Axis in Cancer Therapy

  2017cites this paper
• Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review

  2017cites this paper
• The Inhibition of Chk1/Chk2 and Wee-1 Kinases as a Promising Therapy for the Treatment of Adult Acute Lymphoblastic Leukemia

  2016cites this paper
• ATM Mutations in Cancer: Therapeutic Implications

  2016cites this paper
• In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia

  2015cites this paper
• Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design

  2015cites this paper
• Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma

  2015cites this paper
• The constitutive activation of the DNA damage responsepathway is a novel therapeutic targetin aggressive B-cell lymphoma

  2015cites this paper
• An evaluation of the checkpoint kinase inhibitor V158411

  2015cites this paper
• Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising

  2014cites this paper
• Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma

  2014cites this paper
• Cancer Therapy : Preclinical Gemcitabine and CHK 1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma

  2014cites this paper
• Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors.

  2014cites this paper
• CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress

  2014cites this paper
• Targeting ATR in DNA damage response and cancer therapeutics.

  2014cites this paper
• Combined CDKN1A/TP53 Mutation in Bladder Cancer Is a Therapeutic Target

  2014cites this paper
• Synergy of Bosutinib and Chk-1 Inhibitor (PF) in Chemotherapy

  2014cites this paper
• Pharmacokinetic and pharmacodynamic challenges of Antibody-Directed Enzyme Prodrug Therapy (ADEPT)

  2014cites this paper
• The role of Porphyromonas gingivalis in the regulation of epithelial-mesenchymal transition markers in migration.

  2014cites this paper
• Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer

  2014cites this paper
• Targeted radiosensitization by the Chk1 inhibitor SAR-020106.

  2013cites this paper
• Small Molecule Therapeutics Identi fi cationof PreferredChemotherapeutics forCombining with a CHK 1 Inhibitor

  2013cites this paper
• Monitoring metabolic responses to chemotherapy in single cells and tumors using nanostructure-initiator mass spectrometry (NIMS) imaging

  2013cites this paper
• Antimitotic drugs in cancer chemotherapy: promises and pitfalls.

  2013cites this paper
• Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor

  2013influential citation
• ATR as a Therapeutic Target

  2013cites this paper
• Neuroblastoma and MYCN.

  2013cites this paper
• HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1.

  2013cites this paper
• Targeting the S and G2 checkpoint to treat cancer.

  2012cites this paper
• Genistein abrogates G2 arrest induced by curcumin in p53 deficient T47D cells

  2012cites this paper
• RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma

  2011influential citation
• Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.

  2011cites this paper
• Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo.

  2011cites this paper
• Anticancer therapy with checkpoint inhibitors: what, where and when?

  2011cites this paper
• [18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells

  2011cites this paper
• Development of radiotracers for oncology – the interface with pharmacology

  2011cites this paper
• Methods to study cancer therapeutic drugs that target cell cycle checkpoints.

  2011cites this paper
• Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation

  2011cites this paper
• Defective Cell Cycle Checkpoints as Targets for Anti-Cancer Therapies

  2011cites this paper
• Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

  2011influential citation
• New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

  2010cites this paper
• Context-Dependent Cell Cycle Checkpoint Abrogation by a Novel Kinase Inhibitor

  2010cites this paper
• PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity

  2010cites this paper
• Fully Human Monoclonal Antibody against R adherin with Antitumor and Antimetastatic Activity

  2010cites this paper
• The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.

  2010cites this paper
• Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes

  2010cites this paper